Effects of Velusetrag (TD‐5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation
Authors:
- 9 December 2009
- journal article
- research article
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 22 (1) , 42-e8
Abstract
Abstract Velusetrag (TD‐5108) is a potent, selective high intrinsic activity serotonin 5‐HT4 receptor agonist. We assessed effects of Velusetrag on gastrointestinal transit and compared its pharmacokinetics in healthy volunteers (HV) and chronic constipation (CC) patients. Sixty HV were randomly assigned, double‐blind to placebo, 5, 15, 30 or 50 mg Velusetrag (single and 6‐day dosing). Primary endpoints were colonic transit (geometric centre at 24 h, GC24) and ascending colon emptying (ACE) T1/2 after first dose. Secondary endpoints included gastric emptying (GE) T1/2 and colonic filling at 6 h (CF6). Single dose Velusetrag significantly accelerated GC24, ACE T1/2, and CF6; 30 and 50 mg Velusetrag accelerated all three endpoints. With multiple doses, Velusetrag 30 mg accelerated GC24, and overall accelerated GE T1/2 at 15–50 mg. Pharmacokinetics studies showed dose proportionality in health, and no significant differences between health and chronic constipation with a 15 mg oral dose of Velusetrag. Stimulation of bowel function after15 mg Velusetrag was similar in CC and controls. There were no serious adverse events; notable adverse events were the predictable gastrointestinal effects such as diarrhoea or altered bowel movements. Velusetrag significantly accelerated intestinal and colonic transit after single dosing and accelerated gastric emptying after multiple dosing. Further studies of its potential as a gastrointestinal and colonic prokinetic are warranted.Keywords
This publication has 23 references indexed in Scilit:
- Selective desensitization of the 5‐HT4receptor‐mediated response in pig atrium but not in stomachBritish Journal of Pharmacology, 2009
- T1389 TD-5108, a Selective 5-HT4 Agonist, Is Consistently Better Than Placebo Regardless of Response Definition in Patients with Chronic ConstipationGastroenterology, 2008
- Effect of 5 Days Linaclotide on Transit and Bowel Function in Females With Constipation-Predominant Irritable Bowel SyndromeGastroenterology, 2007
- Pharmacodynamic effects of a novel prokinetic 5‐HT4 receptor agonist, ATI‐7505, in humansNeurogastroenterology & Motility, 2006
- Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006
- Effect of tegaserod on gut transit in male and female subjectsNeurogastroenterology & Motility, 2005
- The 5‐HT4 receptor agonist, tegaserod, is a potent 5‐HT2B receptor antagonist in vitro and in vivoBritish Journal of Pharmacology, 2004
- Tegaserod, a 5‐HT 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjectsAlimentary Pharmacology & Therapeutics, 2001
- Stool Form Scale as a Useful Guide to Intestinal Transit TimeScandinavian Journal of Gastroenterology, 1997
- Towards a less costly but accurate test of gastric emptying and small bowel transitDigestive Diseases and Sciences, 1991